Research programme: NIPEP CARE peptide therapeutics - NIBEC
Alternative Names: NIPEP-CARE; NIPEP-CARE3Latest Information Update: 07 Feb 2025
At a glance
- Originator NIBEC
- Class Anti-inflammatories; Antirheumatics; Hepatoprotectants; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Non-alcoholic steatohepatitis; Rheumatoid arthritis
Most Recent Events
- 24 Jan 2025 NIBEC has patent pending for peptide capable of binding to biomarker for inflammatory and metabolic diseases, and use thereof in South Korea
- 24 Jan 2025 NIBEC has patent protection for peptide capable of binding to biomarker for inflammatory and metabolic diseases, and use thereof in USA and China
- 24 Jan 2025 NIBEC has patents pending for peptide for preventing and treating fibrosis in Europe, China, USA and worldwide